We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $269M
1-Year Est. Return 103.38%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$249M
AUM Growth
-$35.6M
Cap. Flow
-$7.85M
Cap. Flow %
-3.15%
Top 10 Hldgs %
65.95%
Holding
50
New
11
Increased
8
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$15.7M
2
VOR icon
Vor Biopharma
VOR
+$9.87M
3
CLDX icon
Celldex Therapeutics
CLDX
+$9M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$7.43M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.17M

Top Sells

Rank Stock Value
1
ATYR
aTyr Pharma
ATYR
+$13.6M
2
CYTK icon
Cytokinetics
CYTK
+$12.4M
3
CGON icon
CG Oncology
CGON
+$11.3M
4
REPL icon
Replimune Group
REPL
+$10.8M
5
DFTX
Definium Therapeutics
DFTX
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
2 Miscellaneous 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCTH icon
1
Delcath Systems
DCTH
$567M
$30.6M 12.31%
3,300,389
– –
XERS icon
2
Xeris Biopharma Holdings
XERS
$1.55B
$18.7M 7.53%
3,231,700
+1,120,000
+53% +$7.43M
FENC icon
3
Fennec Pharmaceuticals
FENC
$430M
$17.9M 7.19%
2,908,201
+294,693
+11% +$2.28M
SVRA icon
4
Savara
SVRA
$1.08B
$17.5M 7.03%
3,203,721
-200,000
-6% -$1.11M
PCVX icon
5
Vaxcyte
PCVX
$8.9B
$16.9M 6.77%
+290,000
New +$15.7M
EYPT icon
6
EyePoint Inc
EYPT
$386M
$13.4M 5.37%
1,036,737
+346,737
+50% +$5.18M
XFOR icon
7
X4 Pharmaceuticals
XFOR
$401M
$13.3M 5.33%
3,214,766
+608,846
+23% +$2.28M
VOR icon
8
Vor Biopharma
VOR
$1.34B
$12.5M 5.02%
+700,000
New +$9.87M
MDWD icon
9
MediWound
MDWD
$163M
$12.1M 4.85%
749,054
– –
VSTM icon
10
Verastem
VSTM
$654M
$11.3M 4.55%
2,138,475
+350,000
+20% +$2.16M
CLDX icon
11
Celldex Therapeutics
CLDX
$3.07B
$10.5M 4.21%
+330,000
New +$9M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.51B
$8.79M 3.53%
+923,057
New +$7.17M
HELP
13
Cybin Inc
HELP
$890M
$7.35M 2.95%
1,531,814
-125,726
-8% -$813K
CGON icon
14
CG Oncology
CGON
$6.59B
$6.77M 2.72%
100,000
-200,000
-67% -$11.3M
NSPR icon
15
InspireMD
NSPR
$39.8M
$6.37M 2.56%
3,905,743
– –
AVIR icon
16
Atea Pharmaceuticals
AVIR
$430M
$6.3M 2.53%
+1,171,855
New +$5.38M
PROF
17
Profound Medical
PROF
$250M
$5.37M 2.16%
828,118
-240,837
-23% -$1.66M
VRDN icon
18
Viridian Therapeutics
VRDN
$2.61B
$4.9M 1.97%
250,401
-199,599
-44% -$5.93M
REPL icon
19
CALL
Replimune Group
REPL
$1.46B
$2.75M 1.1%
1,275,600
+1,044,700
+452% +$7.99M
PYPD icon
20
PolyPid
PYPD
$103M
$2.62M 1.05%
597,926
-98,630
-14% -$436K
MYO icon
21
Myomo
MYO
$63.4M
$2.6M 1.04%
3,847,272
+7,500
+0.2% +$6.15K
TLPH icon
22
Talphera
TLPH
$62.3M
$2.51M 1.01%
3,353,916
-225,357
-6% -$204K
OVID icon
23
Ovid Therapeutics
OVID
$547M
$2.46M 0.99%
+1,107,994
New +$1.98M
DFTX
24
Definium Therapeutics
DFTX
$5.51B
$2.36M 0.95%
125,000
-625,000
-83% -$10.6M
OKUR
25
OnKure Therapeutics
OKUR
$153M
$1.84M 0.74%
443,763
-286,725
-39% -$885K
1
2

Similar funds

GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
AFO
Allie Family Office Miami, Florida $269M AUM 20.2% 1-Year Est. Return
TW
Titan Wealth St Peter Port $269M AUM
PM
Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return
ZEP
Zeno Equity Partners London, United Kingdom $269M AUM 6.35% 1-Year Est. Return
LBW
Landesbank Baden-Wuerttemberg Stuttgart Baden-Wuerttemberg, Germany $269M AUM
VP
Verisail Partners Chamblee, Georgia $270M AUM 16.03% 1-Year Est. Return
5W
5T Wealth Napa, California $269M AUM 17.81% 1-Year Est. Return

Rosalind Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Rosalind Advisors held 50 positions worth $249M, down 13% from $285M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Rosalind Advisors withdrew a net $7.85M in Q1 2026, closing 14 positions and reducing 11 holdings. Its most notable exit was aTyr Pharma, an estimated $13.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

Against the trend, Rosalind Advisors opened a new position in Vaxcyte worth $16.9M.

  • Rosalind Advisors's largest Q1 2026 buy was Vaxcyte: 290,000 shares worth $16.9M.
  • Rosalind Advisors added most to Xeris Biopharma Holdings in Q1 2026, an estimated $7.43M increase.
  • Rosalind Advisors's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $11.3M.
  • Rosalind Advisors fully exited aTyr Pharma in Q1 2026, selling an estimated $13.6M.
  • Rosalind Advisors's ten largest holdings make up 66% of its $249M portfolio in Q1 2026.
  • Rosalind Advisors opened 11 new positions and closed 14 in Q1 2026.
  • Rosalind Advisors's portfolio value fell 13% quarter-over-quarter to $249M.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.